TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01653912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183 in combination with carboplatin and paclitaxel
Description: Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
Study: NCT00591981

Intervention type: BEHAVIORAL
Intervention: TOGA Tools
Description: ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
Study: NCT01159080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: routine dose tacrolimus and less myfortic
Description: oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reduced dose tacrolimus and conventional myfortic
Description: low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day
Study: NCT01703624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrronium bromide
Description: glycopyrronium bromide suspension in HFA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrronium bromide
Description: glycopyrronium bromide suspension in HFA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrronium bromide
Description: glycopyrronium bromide suspension in HFA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrronium bromide
Description: glycopyrronium bromide suspension in HFA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: glycopyrronium bromide
Description: glycopyrronium bromide suspension in HFA
Study: NCT01935518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasudil
Description: All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
Study: NCT02032056

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (10^9 CFU/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (10^8 CFU/day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00368017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 30 mg once a day for 12 weeks
Study: NCT00368017

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 pill once a day for 12 weeks
Study: NCT02630979

Intervention type: BEHAVIORAL
Intervention: Measuring satisfaction, knowledge and bias
Description: Questionnaire based assessment.
Study: NCT06344585

Intervention type: OTHER
Intervention: Drop out patients who had their first access in 2021 were additionally asked to answer to a phone -call questionnaire to assess their motivation of discontinuation
Description: A prospective comprehensive analysis of the data contained within patient charts, encompassing personal histories and demographic details, was extracted from the internal database of the Humanitas Fertility Center. This analysis aimed at elucidating the individual reasons for treatment discontinuation after the initial clinical visit throughout the year 2021. Additionally a tailored questionnaire was administered to patients via telephone by a member of Humanitas Fertility Center staff in July 2023.~The questionnaire was submitted to the patients via a phone call. The questionnaire comprised nine questions with response limited to 'Yes' and 'No' options for all queries.
Study: NCT05018546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irrigation force
Description: RIRS with different irrigation force

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irrigation force
Description: RIRS with different irrigation force
Study: NCT03281395

Intervention type: PROCEDURE
Intervention: Rapid ventricular pacing (RVP)
Description: Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short period of time during dissection of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. RVP technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations and can be lifesaving in the case of an intraoperative bleeding or rupture.

Intervention type: PROCEDURE
Intervention: No rapid ventricular pacing
Study: NCT01560052

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention: Drug: Placebo~Original Cohort:~Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Low Dose cohort:~Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.~Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy
Study: NCT02819960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probio-Tec® BG-VCap-6.5
Description: Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 2,7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT03162614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sporozoite-infected mosquitoes challenge.
Description: Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.~The challenge occurs approximately 90 days (three months) after the last vaccination.~Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs.
Study: NCT02534116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC) therapy
Description: Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gauze dressing
Description: Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
Study: NCT03223467

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
Study: NCT00506597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m\^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m\^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
Study: NCT01336751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: solution for subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 75% insulin lispro protamine suspension and 25 % insulin lispro injection
Description: suspension for subcutaneous injection
Study: NCT02037386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-side branch stent
Description: Implantation of H-side branch stent at coronary bifurcation stenotic lesion
Study: NCT04439617

Intervention type: BIOLOGICAL
Intervention: blood examination
Description: use of the remaining 1-2 ml of blood in samples taken as part of routine care to study mitochondrial function
Study: NCT01022359

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TesioCath
Description: Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LifeCath Twin
Description: Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
Study: NCT03452033

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: H-1337 Placebo
Description: H-1337 Placebo Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 [1]
Description: H-1337 Ophthalmic Solution Concentration 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 [2]
Description: H-1337 Ophthalmic Solution Concentration 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H-1337 [3]
Description: H-1337 Ophthalmic Solution Concentration 3
Study: NCT00787137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG102
Description: A single intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG102
Description: A single intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Phosphate-buffered saline
Study: NCT02869412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Use BCG website

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Intervention
Description: Use passive website

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02761694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vevorisertib
Description: Administered as an oral dose every day or every other day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered as an intramuscular (IM) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered as an intramuscular (IM) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered as an intravenous (IV) infusion.
Study: NCT04741191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer training
Description: Hospital-based ergometer cycling for 20 minutes (Including warm-up and cooldown), 3x/week on alternate days for 6 weeks at 40-60% of VO2max.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: In bed activities (Active ankle and hand pumping exercise\* 15 Rep\* BD AROMS of extremities\* 15 Rep\* BD, Deep breathing exercises\* 15 Rep\* BD, Ambulation (walk 10-15 minutes below fatigue and onset of symptoms level\* BD) for 6 weeks.
Study: NCT05828420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White noise
Description: Each baby was listened to white noise 10 minutes before, during and 20 minutes after the painful attempt.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart sound
Description: Each baby listened to heart sounds at an average rate of 70 beats 10 minutes before, during and 20 minutes after the painful procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Each baby was listened to the music that the mother listened to the most during pregnancy restriction 10 minutes before, during and after the painful attempt.
Study: NCT03825250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Description: Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Description: Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Description: Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control
Study: NCT00003963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.~Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated.
Study: NCT02513823

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2,000 International Units (IU)of vitamin D3
Description: 2,000 IU vitamin D taken daily for 10 weeks
Study: NCT00740714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 with vitamin E
Description: 2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 with vitamin E
Description: 2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo with vitamin E
Description: placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
Study: NCT03628638

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.

Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Subjects participating in the study will have blood sample collected at enrollment. . For any subjects scheduled for a 12 month follow-up, additional blood samples will be collected at 12 months from enrollment.
Study: NCT03002688

Intervention type: OTHER
Intervention: Survey
Description: Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
Study: NCT05006209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One visit root canal treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Two visit root canal treatment
Study: NCT01778322

Intervention type: PROCEDURE
Intervention: Intracranial aneurysm embolization
Description: Treatment of intracranial aneurysms
Study: NCT01961960

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: intramuscular
Study: NCT00359567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron hydrochloride
Description: intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
Study: NCT02980744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour intervention
Description: The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
Study: NCT01902888

Intervention type: DEVICE
Intervention: GORE® VIABAHN® Endoprosthesis
Study: NCT02448888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted exercise
Description: 2 months, 3 times/week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General exercise recommendations
Description: 2 months, 3 times/week
Study: NCT00085254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilengitide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01342744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin(850 mg) 1tab oral twice aday

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tab oral twice a day
Study: NCT00319657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation
Description: Transplantation of hematopoietic stem cells from the living donor.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation
Description: Total lymphoid irradiation is used as part of the conditioning regimen for the hematopoietic stem cell transplant.
Study: NCT02818114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Enhanced Prolonged Exposure
Description: Peer support interventions as adjunct to prolonged exposure